Glucose-regulated protein 78 (GRP78) is a stress sensor which interacts with unfolded protein response (UPR) activators in the endoplasmic reticulum (ER). The aim of this study was to test the hypothesis that GRP78 has distinct functional roles in mediating the effects of ER stress in neuroblastoma compared to other neuroectodermal cancer types. GRP78 was knocked down or overexpressed in neuroectodermal tumour cell lines. Protein and transcript expression were measured using Western blotting, confocal microscopy and real-time polymerase chain reaction; cell stress was assessed by measurement of oxidative stress and accumulation of ubiquitinated proteins and cell response by measurement of apoptosis and cell viability. Neuroblastoma cells were more sensitive to ER stress than melanoma and glioblastoma cells. GRP78 knockdown increased stress sensitivity of melanoma and glioblastoma cells, but not neuroblastoma cells. Over-expression of GRP78 decreased the stress sensitivity of melanoma and glioblastoma cells but, in contrast, increased the stress sensitivity of neuroblastoma cells by activation of caspase-3-independent cell death and substantially increased the expression of UPR activators, particularly inositol-requiring element 1 (IRE1). The results from this study suggest that cell-type specific differences in the relationships between GRP78 and the UPR activators, particularly IRE1, may determine differential sensitivity to ER stress.
Survival in heterogeneous microenvironments is a defining characteristic of metastatic tumour cells, and relies on an ability to adapt to varying degrees and types of stress [Kenific et al., 2010] . Understanding how to abrogate selectively the homeostatic mechanisms allowing cancer cells to survive outside their normal tissue environment is important for developing strategies to limit metastasis. The endoplasmic reticulum (ER) has a key role in sensing stress and in providing the scaffold, quality control and redox environment for correctly assembling newly-synthesised proteins. Disrupting ER function leads to the accumulation of unfolded or mis-folded proteins and activation of the Unfolded Protein Response (UPR), a homeostatic mechanism which may represent a target for controlling tumour metastasis. In this context, the protein-folding chaperone glucose-regulated protein 78 (GRP78) has a key role in sensing ER stress and facilitating adaptive responses.
GRP78 has high affinity for unfolded or mis-folded proteins and interactions with such substrates result in its dissociation from the UPR activators Protein kinase-like ER kinase (PERK), Inositol-Requiring Element 1 (IRE1) and Activating Transcription Factor 6 (ATF6) [Schroder, 2006] . PERK release facilitates kinase activation by autophosphorylationinduced homodimerisation, leading to attenuation of general protein synthesis Harding et al., 1999] , while allowing translation of mRNA for pro-survival and pro-death stress-response proteins ; these proteins include Activating Transcription Factor 4 (ATF4), which in turn stimulates synthesis of chaperones, including GRP78, other proteins involved in homeostasis [Fels, 2006] and, under prolonged or severe stress, the pro-apoptotic transcription factor growth arrest and DNA damage induced gene 153 (GADD153) [Wing et al., 1996] . Negative feedback inhibition of PERK, and eIF2α dephosphorylation [Kebache et al., 2004; Van Huizen et al., 2003] as stress is resolved, restores normal translation capacity.
Once released from GRP78, oligomerization and autophosphorylation of IRE1, a trans-membrane protein kinase endoribonuclease, results in RNase-domain activation and splicing of mRNA for X-box binding protein 1 (XBP-1). Downstream events of IRE1 activation include regulation of ER-resident chaperones and promotion of death via activation of GADD153and c-Jun N-terminal kinase (JNK) [Urano et al., 2000] . IRE1 also phosphorylates tumour necrosis factor receptor 2 (TRAF2) leading to activation of JNK and caspase-independent apoptosis via Bax and pro-apoptotic factors [Kroemer et al., 2007] . ATF6 released from GRP78 is cleaved in the Golgi to an active transcription factor which binds to promoters containing ER-stress response elements and regulates expression of ERstress-related proteins such as GRP78, XBP-1 and GADD153 [Yoshida et al., 2000] . Although PERK, IRE1 and ATF6 appear to have separate roles in stress signalling, ATF6 has functional overlap with PERK and IRE1 signalling pathways.
Recent studies to understand the cellular role of GRP78 in tumour cells have suggested that increased GRP78 expression in melanoma and glioblastoma promotes cell survival and correlates with poor prognosis [Hersey and Zhang, 2008; Lee et al., 2008; Liquing et al., 2009] ; conversely, increased GRP78 expression in neuroblastoma may correlate with greater stress sensitivity and better prognosis [Hsu et al., 2005] . These conflicting reports imply that GRP78 has different roles as a sensor of ER stress in different types of neuroectodermal tumours. The aim of this study was to test the hypothesis that GRP78 has functionally-or mechanistically-distinct roles in mediating the effects of ER stress in neuroblastoma compared to other neuroectodermal cell types.
MATERIALS AND METHODS

GROWTH AND MAINTENANCE OF CELL LINES
SH-SY5Y and NGP human neuroblastoma cells were cultured in RPMI 1640, 10% foetal bovine serum (FBS). U251 and MO59J human glioblastoma and CHL-1 and WM266-4 (ATCC #; CRL-9446, CRL-1676) human melanoma cells were cultured in high glucose (4.5 g/L) DMEM, 10% FBS. All media were from Sigma-Aldrich (Poole, UK). Cells were regularly tested for mycoplasma and maintained at 37 °C, 5% CO 2 in air (humidified), for up to 50 passages. Bortezomib (Janssen Cilag Ltd, High Wycombe, UK) was added to cultures in DMSO, and fenretinide (Janssen-Cilag, Switzerland) in ethanol.
CELL DEATH
Seeding densities (cells per well) for overnight attachment in flat-bottomed 6-well plates were 1.5 x 10 5 for CHL-1, 2.0 x 10 5 for U251, MO59J, SH-SY5Y and NGP, and 2.5 x 10 5 for WM266-4 cells. FACScan or FACScalibur flow cytometers (Becton Dickinson Immunocytometry systems, Oxford, UK) were used to record the percentage of propidium iodide-stained cells with hypodiploid DNA (subG1 peak) as a measure of cell death as described previously [Lovat et al., 2008; Lovat et al., 2004] .
ANALYSIS OF CELLULAR PROTEINS
Proteins were analysed by gel electrophoresis and Western blotting, using β-actin as a reference after loading in each gel lane equivalent amounts of protein or protein from the same number of cells. Protein was measured with a Bradford assay (Pierce Biotech., Rockford, IL) using a bovine serum albumin (BSA) standard; cells were counted using a ViCell counter (Beckman Coulter, Dunstable, UK). Cell lysates were prepared and analysed by Western blotting using 4-20% Tris-glycine polyacrylamide gels (Bio-Rad laboratories, Hemel Hempstead, UK) as described previously [Armstrong et al., 2007] . Antibodies and dilutions used to probe blots were for the GRP78 C-Terminus (Santa Cruz, sc1051; 1:1000 dilution), Cleaved Caspase 3 (Cell Signalling, 9661L; 1:500), PERK (Santa Cruz, sc9481; 1:2000), IRE1 α (Santa Cruz, sc20790; 1:2000), ATF6 α (Santa Cruz, sc-14253; 1:500), ATF4 (Calbiochem, PC715; 1:500), , , Ubiquitin (Cell Signalling [P4D1], #3936; 1:1000) and β-actin (Sigma-Aldrich, A2228; 1:5000). Horseradish peroxidase-conjugated secondary antibodies (Upstate Biotechnology, Boston, USA; diluted 1:2000) were used for detection with the ECL-plus system (Amersham Biosciences, Little Chalfont, UK) with imaging on a Fujifilm FLA-3000 fluorescence imager (Raytek Scientific Ltd, Sheffield, UK). Aida Image Analyser version 3.28 was used for densitometric quantification relative to control treatments. For ATF4, data were expressed as 'attomoles/cell' (amoles/cell) by reference to a standard consisting of a 26 kDa His-tagged ATF4 fragment consisting of amino acids 123-351from Abcam (Cambridge, UK). Estimates of cell and nuclear diameters were obtained from phase contrast images and 4',6-diamidino-2-phenylindole (DAPI) -stained confocal microscopy images of detached spherical cells. Cytosolic concentrations of ATF4 were then estimated using the mean cytosolic volumes calculated from mean cell and nuclear diameters of detached cells.
FLOW CYTOMETRY FOR THE INDUCTION OF REACTIVE OXYGEN SPECIES (ROS)
Cells were seeded into 6-well plates (as above) before treatment with ER stress-inducing agents over a 6 h time course. After treatment, culture medium was removed and cells washed twice in PBS before harvesting by trypsinisation, pelleted by centrifugation at 330 g for 5 min and resuspended in 500 µl of 5 µM 5-(and-6)-Carboxy-2',7'-Dichlorofluorescein Diacetate (DCFDA, Sigma-Aldrich). Samples were then incubated at 37 °C for 15 min, washed twice in ice-cold PBS by centrifugation and stored on ice for analysis by flow cytometry. Negative controls were unstained cells and working dye solution alone, and positive controls were cells treated with 25 µM and 50 µM hydrogen peroxide for 6 h (Sigma-Aldrich). Flow cytometry data were collected using CellQuest v. 3.3 software using a gated amplifier for FL1 (λ 530/30 nm; fluorescein) and a signal threshold for forward and side scatter to exclude debris.
SMALL INTERFERING RNA (SIRNA)-MEDIATED KNOCKDOWN OF GRP78
Knockdown of GRP78 was performed using a double-transfection procedure as described by Martin et al (2010) using GRP78 siRNA (Hs_HSPA5_6_HP validated siRNA; Qiagen, Crawley, UK) or control scrambled siRNA (Qiagen). Knockdown was verified by Western blot 24 h after the second transfection or when subsequent cell viability and death assays were performed.
REVERSE TRANSCRIPTASE QUANTITATIVE POLYMERASE CHAIN REACTION (RT-QPCR)
Cells were washed (PBS), detached and pelleted by centrifugation, washed once with PBS and total RNA extracted using the RNeasy Kit (Qiagen). To prepare cDNA, 0.5 µg RNA was combined with 0.5 µg random oligo dT primers, 0.5 mM deoxynucleotide triphosphates (dNTPs), and RNase-free water (final volume 20 µl), and incubated at 65 °C for 5 min followed by 1 min on ice; 4 µl of first-strand buffer, 1 µl of 0.1 M DTT, 1 µl of RNase Inhibitor and 1 µl of Superscript Reverse Transcriptase were added and incubated at 55 °C for 60 min before terminating the reaction at 70 °C for 15 min. RNase H (0.5 µl of 5U/µl stock) was added, incubated for 20 min at 37 °C and inactivated at 65 °C for 10 min. All reagents were from Fermentas (St. Leon-Rot, Germany). Real-time PCR reactions (20 µl volume) were carried out in triplicate reactions with PCR primers for GRP78 (GTT CTT GCC GTT CAA GGT GG and TGG TAC AGT AAC AAC TGC ATG) and or β-Actin control (AAT CTG GCA CCA CAC CTT CTA CA and CGA CGT AGC ACA GCT TCT CCT TA) and a 2 x concentration of fast SYBR green master mix containing AmpliTaq fast DNA polymerase, SYBR Green-1 dye and dNTPs with an Applied Biosystems 7500 fast real-time PCR machine with SDS software (Applied Biosystems, Carlsbad, California, USA). PCR conditions were an initial denaturation at 95 °C (10 min), 50 cycles of 15 s at 95 °C and 60 s at 60 °C for GRP78 or 15 s at 95 °C, 45 s at 60 °C and 30 s at 72 °C for β-actin followed by a final cycle of 30 s at 95 °C and 60 s at 60 °C.
STABLE OVER-EXPRESSION OF GRP78
Plasmid DNA pcDNA3.0 or pcDNA3.1 (+) containing full-length GRP78 cDNA (a gift from Randal Kaufman) were transfected into WM266-4, MO59J and NGP cells in 6-well plates at 3.0 x 10 5 cells per well. Plasmid DNA (4 µg in 8 µl) and 12 µl of Lipofectamine 2000 transfection reagent (Invitrogen, Paisley, UK) were mixed separately with 500 µl OptiMEM medium (Invitrogen), combined together at room temperature for 15 min and then diluted with 1.5 ml OptiMEM. Culture medium was removed from the cells, the cells washed with OptiMEM and then incubated with the transfection mixture for 24 h at 37 °C. Medium was then replaced with 3 ml of culture medium containing 10% FBS and 2 mM L-glutamine, and incubated for 48 h at 37 °C before selection with geneticin (G418; Invitrogen) at 1500 µg/ml for neuroblastoma cells and 2000 µg/ml for melanoma and glioblastoma cells. Transfected cells were maintained under G418 selection over 10 passages as a mixed population without clonal selection. For experiments, cells were placed in normal culture media for a minimum of 3 days prior to the start of each experiment.
CONFOCAL MICROSCOPY
Cells were fixed in 100% ice-cold methanol (Fisher; 30 min), washed in PBS containing 0.05% Tween 20 (PBS/T; Sigma-Aldrich) and permeabilised in 0.2% Triton X100 (SigmaAldrich, diluted in PBS/T) for 30 min. After blocking with 2% BSA in PBS/T for 1 h, samples were washed thrice in PBS/T and incubated with GRP78 primary antibody (Santa Cruz; 1:500), in 0.2% BSA-PBS/T for 1 h at room temperature. After washing 3 times in PBS/T, blocking in 10% secondary host-antibody-specific serum in PBS/T for 30 min, samples were incubated with fluorescently-labelled secondary antibodies diluted in 1% hostspecific serum for 1 h. Cell nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) diluted in PBS/T for 25 min. Stained cells were mounted in Vector Shield mounting medium (Vector Laboratories LTD, Peterborough, UK) and imaged within 24 h using a x48 objective on a Zeiss LSM 700 inverted confocal scanning microscope (Zeiss, Hertfordshire, UK) with averaging of 4 and a frame size of 1024 x 1024 pixels. Each experiment included a negative control of unstained cells, as well as secondary antibody only to control for non-specific binding. Laser power, optimised on control-stained cells, remained the same throughout each experiment.
DATA ANALYSES
Flow cytometry data were analysed using either WinMDI 2.8 for flow cytometry (Biosoft.net) or Cyflogic 1.2.1 (Cyflogic, Turku, Finland). Real time PCR data were analysed using SDS2.2 software (Applied Biosystems). The threshold level of expression was set to a value on the exponential phase of amplification plots and kept the same for all related primerprobe experiments. The PCR cycles taken to reach the threshold (Ct) for each sample was generated as mean ± 95% confidence intervals (CI) normalised to the β-Actin control data and then to the vehicle-treated control samples. Experimental data were expressed as the mean of individual experiments ± 95% confidence intervals (95% CI) using Prism 5 (GraphPad Software Inc; La Jolla, CA, USA) or Sigma Plot 11 (Systat Software Inc; San Jose, CA, USA) software. Responses were compared by one-or two-way ANOVA with either Dunnett's or the more-conservative Bonferroni's post-hoc tests using Prism 5, SPSS release 17.0 (IBM; Chicago, IL, USA) or R software. Error bars on all graphs are 95% confidence intervals. Dose response parameters were fitted using R and the package drc [Ritz and Streibig, 2005] .
RESULTS
RESPONSES TO STRESS-INDUCING AGENTS IN NEUROECTODERMAL CELL LINES
For this work, we studied six cell lines in parallel: two melanoma (CHL1, WM266-4), two glioblastoma (U251, MO59J) and two neuroblastoma (SH-SY5Y, NGP) cell lines. Fenretinide and bortezomib induce ER stress in melanoma and neuroblastoma cells [Hill et al., 2009; Pagnan et al., 2009 ] by oxidative stress [Lovat et al., 2000] and 26S proteasome inhibition, respectively. For the six cell lines, sensitivity and responses to fenretinide and bortezomib were characterised in terms of cell death at 24 h and the induction of the stress marker ATF4 after 4 h of treatment. For neuroblastoma and melanoma cells, dose-response data indicated maximum cell death of 30-50% but differing sensitivities between cell types with 10-fold lower concentrations of bortezomib and 2-fold lower concentrations of fenretinide required for neuroblastoma cells ( Figure 1A) . Conversely, glioblastoma cells had higher levels of death (up to 80%; Figure 1A ) but within a similar sensitivity range to melanoma cells. ATF4 induction was evident in all cell lines but to differing levels and was induced to 3-to 10-fold higher levels in melanoma cells compared to neuroblastoma cells with intermediate levels of induction observed for glioblastoma cells ( Figure 1B ).
With doses in the mid-range of response, fenretinide rapidly induced reactive oxygen species (ROS) in all six cell lines, reaching a plateau after 2-4 h but at higher steady-state levels in melanoma than neuroblastoma cells and, again, intermediate values in glioblastoma cells (Figure 2A ). ATF4 was induced by fenretinide over a similar time course, rather more transiently in melanoma cells but remaining elevated in glioblastoma cells ( Figure 2B ), and to lower levels in neuroblastoma cells. In response to bortezomib, ubiquitin decreased and ubiquitinated proteins increased steeply during the first 8 h ( Figure 2C, E) . Greatest increases in ubiquitinated proteins, relative to the zero h controls, were produced in glioblastoma cells, reaching 20-fold by 24 h, with lower levels in melanoma cells (8-to 10-fold increase by 24 h) and very small increases in neuroblastoma cells (1.5-fold increase by 8-24 h; Figure 2C ,E). ATF4 increased over a similar time scale, reaching a peak by 4-8 h and remaining substantially elevated until at least 24 h ( Figure 2D ).
CELL DEATH AFTER GRP78 KNOCKDOWN
To test the role of GRP78 in drug and stress sensitivity, GRP78 expression was reduced by RNA interference. We have previously reported the siRNA-mediated knockdown of GRP78 in CHL-1 and WM266-4 cells and used the same technique to achieve a modest reduction in GRP78 expression of > 50% in all cell lines, ranging from 56.3% in CHL-1 cells to 82.3% in U251 glioblastoma cells. Treatment with fenretinide or bortezomib resulted in the induction of GRP78 as part of the stress response, and this was abrogated after knockdown of GRP78 (Figure 3 and ).
Knockdown of GRP78 increases cell death of melanoma cells in response to fenretinide or bortezomib . For glioblastoma cells, GRP78 knockdown also resulted in statistically-significant increases in death in response to fenretinide or bortezomib ( Figure 3A , B), similar to melanoma cells. Conversely, death was not significantly increased in either of the neuroblastoma cell lines ( Figure 3C , D) and there was a small but statistically-significant decrease in death of fenretinide-treated SH-SY5Y cells ( Figure 3D ). These results were confirmed in experiments to measure the effect of GRP78 knock-down on stress-induced inhibition of cell viability ( Figure S1 ).
Increased sensitivity to stress would be predicted from GRP78 knockdown, but in view of the fact that GRP78 interacts directly with the stress sensors, it is important to ask if there are correlated or compensatory alterations in expression of PERK, IRE1 and ATF6 as a result of GRP78 knockdown. For melanoma cells, there was no apparent effect on GRP78 knockdown on ATF6 or PERK expression but a 1.3-fold increase in IRE1 expression ( Figure  4A ). UPR activator expression overall was reduced slightly (by up to 0.9-fold) in glioblastoma cells ( Figure 4B ). Conversely, there were no significant changes in UPR activator levels in the neuroblastoma cells in response to GRP78 knockdown ( Figure 4C) . Overall, the magnitudes of changes in UPR activator levels were small in comparison to the > 50% knockdown of GRP78.
RESISTANCE AND SENSITIVITY TO STRESS AFTER OVER-EXPRESSION OF GRP78
To test the prediction that increasing GRP78 expression would increase resistance to stress, GRP78 was stably over-expressed in one cell line of each type: WM266-4 melanoma, MO59J glioblastoma and NGP neuroblastoma cells. Compared to cells stably transfected with empty vector, in GRP78-transfected cells, GRP78 mRNA was increased 1.5-to 2-fold. Similarly, GRP78 protein increased by 1.7-fold in melanoma, 1.96-fold in glioblastoma and 1.5-fold in the neuroblastoma cells ( Figure 5A , B) and this was confirmed by confocal microscopy which also showed increased GRP78 staining with similar intracellular distributions to control cells ( Figure 5C, D) .
Unlike WM266-4 and MO59J cells, over-expression of GRP78 in NGP neuroblastoma cells resulted in morphological changes: cells increased in size with a decrease in dendrites and an increase in detachment ( Figure 6A, B) . Over-expression of GRP78 in all three cell lines affected sensitivity to fenretinide or bortezomib with reduced death in WM266-4 and MO59J cells (Figure 6C, D) . However, NGP neuroblastoma cells showed increased sensitivity to stress and the death of the vehicle-treated control cells was increased compared to vector-transfected or wild-type cells ( Figure 6E ). These effects, although relatively small, were mirrored by increased viability of WM266-4 and MO59J cells overexpressing GRP78 and treated with fenretinide or bortezomib, but decreased viability of NGP cells under the same conditions ( Figure S2 ). For confirmation of effects on neuroblastoma cells, we transiently over-expressed GRP78 in NGP cells in the absence of ER stress. Death of these cells was increased in a GRP78-dose-dependent manner 24 h after transfection ( Figure 6F ) and confirmed the results from stable over-expression experiments that, contrary to prediction, higher levels of GRP78 expression increased neuroblastoma cell death and reduced survival.
With respect to biochemical markers of cell stress and death, the induction of ATF4 and cleavage of caspase-3 in response to fenretinide or bortezomib were measured ( Figure  7A -C). In stressed WM266-4 and MO59J cells overexpressing GRP78, ATF4 induction and caspase-3 cleavage were significantly reduced. Conversely, the over-expression of GRP78 increased ATF4 induction in NGP neuroblastoma cells treated with bortezomib but decreased ATF4 induction in response to fentretinide compared to control vector-transfected cells; unexpectedly, however, caspase-3 cleavage in these NGP cells was also reduced in response to both drugs, despite the increased levels of cell death ( Figure 6 ) produced under these conditions.
For all three cell types there were no significant differences in UPR activator expression between wild-type cells and those stably transfected with empty vector; in contrast, IRE1 expression was increased 2-fold in WM266-4 cells over-expressing GRP78 and accompanied by a small decrease in ATF6 expression ( Figure 7D ,E). In MO59J cells over-expressing GRP78, PERK expression was reduced by 50% whereas for NGP cells, GRP78 over-expression resulted in increased levels of all three UPR activators, with marked ≈3-fold increases in IRE1 and ATF6, as well as a small increase in PERK.
STRESS AFTER GRP78 OVER-EXPRESSION
These results provide evidence that neural-crest-derived tumour cell types differ in how stress-sensor functions of GRP78 are modulated to determine the outcome of stress. Given the dynamic nature of cellular homeostatic control, it is important to ask if stress apparently experienced by cells is altered by GRP78 over-expression. In WM266-4 and MO59J cells stably over-expressing GRP78, fenretinide-induced ROS was inhibited; however, this was not the case when GRP78 was over-expressed in NGP neuroblastoma cells ( Figure 8A ). With respect to cells treated with bortezomib, the accumulation of ubiquitin-tagged proteins was reduced by GRP78 over-expression in WM266-4 and MO59J cells ( Figure 8B ) but increased in NGP cells. Thus, reduced death in response to bortezomib in cells over-expressing GRP78 was associated with a reduced ability of bortezomib to inhibit 26S proteasome activity. Conversely, although fenretinide-induced ROS and death were reduced in melanoma and glioblastoma cells by over-expressing GRP78, in neuroblastoma cells the higher levels of fenretinide-induced death with GRP78 over-expression were not accompanied by increased ROS ( Figure 8A ).
DISCUSSION
Fenretinide and bortezomib both activate the PERK/ATF4 arm of the UPR [Lai and Wong, 2008; Obeng et al., 2006] but do so to differing extents. The steady accumulation of ubiquinated proteins induced with bortezomib implies a sustained effect with stress increasing over time, reflected by the high and continued expression of the ER stressinducible marker ATF4. In contrast, ROS induced by fenretinide reached a maximum after only a few hours and induced a transient ATF4 expression, implying adaptation to higher ROS levels. Despite apparent differences in mechanisms, levels of death induced by each agent were apparently cell-type specific. Although we discuss our data in the context of intracellular GRP78, some studies have suggested that using antibodies to modulate activity of cell-surface GRP78 may affect stress sensitivity [Liu et al., 2013; Misra et al., 2009] . However, we have been unable to demonstrate (Martin, Lovat, Redfern unpublished data) a convincing effect of an anti-GRP78 antibody on increasing the sensitivity of melanoma, glioblastoma or neuroblastoma cells to stress-inducing drugs. Therefore, it is likely that the role of GRP78 in the context of our studies is mediated by intracellular signalling pathways.
Reducing GRP78 expression may increase stress sensitivity, perhaps by reduced chaperone capacity or by priming the UPR as a consequence of excess unbound UPR activators. As with the melanoma and glioblastoma cell lines used for this study, increased stress sensitivity resulting from reductions in GRP78 expression has also been reported for breast cancer and HeLa cells [Cook et al., 2012; Suzuki et al., 2007] . The consequence of GRP78 knockdown is likely, on the basis of simple mass-action models of the association and dissociation kinetics of GRP78 with each of the UPR activators, to lead to increases in levels of free IRE1, PERK and ATF6. Although IRE1 can have pro-survival and proapoptotic functions, such potential changes in UPR activators could drive increased sensitivity of cells to stress. However, neuroblastoma cells did not show increased sensitivity to stress after GRP78 knockdown, implying a contextual relationship between GRP78, UPR activators and stress sensitivity.
The converse experiment, increasing GRP78 levels by stable over-expression, produced the predicted result in WM266-4 melanoma and MO59J glioblastoma cells, reducing death in response to stress. In contrast to transient knockdown experiments, stable over-expression of GRP78 was accompanied by variable but relatively large changes in UPR activator expression, with reductions in PERK in the glioblastoma cells and increased IRE1 but decreased ATF6 in melanoma cells. The contribution of these changes in UPR activator expression to decreased stress sensitivity is uncertain because GRP78 over-expression in these cells was also accompanied by reduced stress in response to fenretinide or bortezomib. In marked contrast, GRP78 over-expression in the NGP neuroblastoma cells increased stressinduced death, possibly as a result of the large and unexpected increases in expression of all three UPR activators. There was also a marked phenotypic change in these cells which may indicate a functional role for GRP78 in morphogenesis and differentiation, either directly [Barnes and Smoak, 2000] or as a result of changes in expression of UPR activators, particularly IRE1 or downstream transcription factors such as XBP1 [Cho et al., 2013] , or interaction with other chaperones [Gunter and Degnan, 2007] .
GRP78 is involved in the regulation of redox levels as a stress response via the PERK-dependent activation of Nrf2 and up-regulation of redox-defensive genes [Cullinan et al., 2003; Niture et al., 2010] . Others have shown that GRP78 knockdown can increase endogenous ROS levels, but subsequent effects of stress-inducing agents are unpredictable [Chang et al., 2012] . Therefore, reduction in ROS in melanoma and glioblastoma cells overexpressing GRP78 and treated with fenretinide is consistent with a role of GRP78 in redox regulation, although whether mediated directly by GRP78 or indirectly via PERK is unknown. Reductions in bortezomib-induced accumulation of ubiquitinated proteins in melanoma and glioblastoma cells over-expressing GRP78 may result from an increase in chaperone capacity. GRP78 may have a role in ERAD by interacting with the E3 Ubiquitin ligase HRD-1 [Sasagawa et al., 2007] and a ubiquitin hydrolase [Fang et al., 2012] ; such interactions in cells over-expressing GRP78 could decrease the accumulation of ubiquitinated proteins in response to bortezomib. GRP78 can also inhibit caspases mediating ER-stressinduced apoptosis [Reddy et al., 2003] , an additional mechanism that could lead to decreased stress sensitivity of WM266-4 and MO59J cells over-expressing GRP78, and to increased sensitivity under knockdown conditions. Thus, in melanoma and glioblastoma cells under conditions of high GRP78 expression, reduced stress sensitivity may result from reductions in free UPR activators (predicted by considering mass-action relationships), caspase inhibition and reduced levels of stress (greater first-line stress defences); conversely, after GRP78 knockdown, higher levels of free UPR activators and low caspase inhibition, potentially coupled with reduced stress defences, would increase stress sensitivity.
GRP78 seems to act as a buffer for regulating IRE1 activity [Pincus et al., 2010] and for neuroblastoma cells it is possible that the effect of manipulating GRP78 levels may be driven by IRE1 and interactions coupling IRE1 to death pathways other than the PERK/ATF4 axis. Levels of ubiquitinated-protein accumulation in these cells were, compared to melanoma and glioblastoma cells, high under basal conditions and changed little in response to bortezomib. As well as binding to GRP78, IRE1 interacts with HRD-1 [Gao et al., 2008] , presenilin-1 [Niwa et al., 1999] , TRAF2 [Urano et al., 2000] , TAO kinase 3 [Yoneda et al., 2001] and MAP3K5 (ASK1) [Nishitoh et al., 2002] . TRAF2, TAO Kinase 3 and ASK1 are components of the ASK1-JNK pathway leading to apoptosis by both caspase-dependent andindependent mechanisms; in neuronal cells, caspase-independent apoptosis via a kinaseindependent ASK1/Daxx interaction [Charette et al., 2001] and JNK-dependent pathways [Kamalden et al., 2012] have been described. As caspase-3 cleavage was not a feature of increased stress-induced cell death in NGP cells over-expressing GRP78, apoptosis under these conditions may be driven by caspase-3-independent processes resulting from increased IRE1 levels. IRE1 is also a component of the ERAD/ubiquitination system via its interaction with HRD-1 [Gao et al., 2008] and in the transcriptional regulation of ERAD components ; therefore, increased accumulation of ubiquitinated proteins in bortezomibtreated cells may also result from higher IRE1 levels.
It is clear from this and other studies that GRP78 has complex roles in cell signalling, stemming from its interactions from the three stress sensors as well as with other proteins. In breast cancer cells, apoptosis may be regulated by interactions between GRP78 and the proapoptotic BH3-domain protein Bik [Zhou et al., 2011] ; thus, changes in the availability of free Bik as a result of GRP78 over-expression or knockdown could be a contributory factor to the increased resistance or sensitivity, respectively, seen in melanoma and glioblastoma cells. Nevertheless, the results from this study suggest that cell-type specific differences in the relationships between GRP78 and the UPR activators, particularly IRE1, may determine differential sensitivity to ER stress. For IRE1 there are likely to be complex relationships between monomer (kinase inactive) IRE1, active IRE1 oligomers, GRP78 and IRE1-interacting proteins such as TRAF2, HRD-1, ASK1 and TAO Kinase 3 and interpreting the outcome of changes in expression of one or more of these components will require computational approaches to couple signalling fluxes to cellular outcome in terms of adaptation (homeostasis/repair) or cell death, coupled with experimental measurements of stoichiometric relationships between GRP78 and UPR activators in relation to stress sensitivity. Figure S1 Figure S2 
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Figure 3:
SiRNA-mediated knockdown of GRP78 measured by Western blotting and densitometric quantification (left column) and sensitivity to ER-stress-induced cell death (right column). Published data for melanoma cells from the study of In the left-hand column, bar height is mean expression of GRP78 relative to the control-transfected and control-vehicle-treated cells and corrected for loading using the β-actin intensity; example blots are shown above each graph. For all cell lines, GRP78 expression (left-hand column) was reduced relative to a scrambled control siRNA by > 50% (one-way ANOVA, Dunnett's post hoc test, P < 0.0001). In the right-hand column, bar height is mean relative cell death (fold change; measured by flow cytometry) expressed relative to untreated, scrambled control-transfected cells. In glioblastoma cells, GRP78 knockdown increased death in response to fenretinide or bortozomib (across siRNA treatments, one-way ANOVA, Dunnett's post hoc test: MO59J P < 0.0001; U251 P < 0.001). There was no increased death in response to fenretinide or bortezomib after GRP78 knockdown in the neuroblastoma cells (P>0.05) but in SH-SY5Y cells treated with fenretinide there was a small decrease in death (one-way ANOVA; Dunnett's, P < 0.05). On the graphs: ***, P <0.001; **, P < 0.01; *, P<0.05; the direction (increase or decrease) of significant change is indicated by an arrow.
Figure 4:
Expression of the UPR activators, PERK, IRE1 and ATF6 in melanoma (A), glioblastoma (B) and neuroblastoma cells (C) after siRNA mediated knockdown of GRP78, relative to control (scrambled) siRNA-transfected cells and corrected for β-actin intensity. Example blots are shown to the right of each graph. On each graph, white/open bars are data for control transfected cells (c) and black bars are GRP78 siRNA-transfected cells (G). Data were analysed by two-way ANOVA for each cell type: initially to test the effect of treatment by cell line (main effects and interactions) for each UPR activator, and then to test the overall relative response with respect to relative UPR activator expression and treatment (main effects and interactions). The ordinate scale is from 0.5 to 1.5. For the melanoma cell lines, there was no significant effect of GRP78 knockdown on ATF6 or PERK expression (twoway ANOVA; P>0.1 and P>0.8, respectively) but a 1.3-fold increase in IRE1 expression (P=0.007; cell line and cell:treatment interactions P>0.9). UPR activator expression overall was reduced (up to 0.9-fold) in glioblastoma cells (treatment effect P=0.009; differences between UPR activator type and interactions, P>0.8). **, P < 0.01; *, P<0.05.
Figure 5:
Over-expression of GRP78 cDNA in a melanoma (WM266-4), glioblastoma (MO59J) and neuroblastoma cell line (NGP) stably transfected with the empty pcDNA3.0 vector or pcDNA3.1 (+) containing GRP78 cDNA (G Curve is cubic function of best fit. In the absence of ER stress, GRP78 cDNA increased cell death dosedependently (one-way ANOVA, F 5, 17 = 138.1, P < 0.0001). Error bars are 95% CI. ***, P <0.001; **, P < 0.01; *, P<0.05; the direction (increase or decrease) of significant change is indicated by an arrow.
Figure 7:
The consequences of GRP78 over-expression: downstream markers of ER stress and cell death after treatment with ER-stress inducing drugs, and UPR activator expression in cells over-expressing GRP78 compared to wild-type cells or cells transfected with empty vector. An analysis of caspase-3 cleavage and ATF4 expression in WM266-4 (left column), MO59J (centre column) and NGP cells (right column) is shown using Western blotting in A, with densitometric quantification in B (caspase-3 cleavage) and C (ATF4 expression). Bar heights and the mean with 95% CI from 3 experiments expressed relative to control-vehicle-treated cells. Caspase-3 cleavage and ATF4 induction in response to fenretinide (F) or bortezomib (B) was reduced in WM266-4 and MO59J cells overexpressing GRP78 (one-way ANOVA for ATF4 and caspase 3 cleavage, fenretinide P < 0.001 or bortezomib P < 0.001). In NGP neuroblastoma cells over-expressing GRP78, caspase-3 cleavage was reduced compared to control vector-transfected cells (P<0.001) in response to fenretinide or bortezomib; conversely ATF4 induction in response to bortezomib was increased (P < 0.0001) but reduced in response to fenretinide treatment (P<0.01).. D, Western blots for UPR activator expression (PERK, IRE1 and ATF6) for the wild-type (c), vector-transfected (v) and GRP78-transfected (G) WM266-4, MO59J and NGP cells. E, Densitometric quantification, relative to wild-type cells: in WM266-4 cells over-expressing GRP78 there was a 2-fold increase in expression of IRE1 and a small decrease in ATF6 expression (one-Way ANOVA with Dunnett's, comparing stablytransfected cells to wildtype, P < 0.0001 for IRE1 and P < 0.01 for ATF6) while MO59J cells over-expressing GRP78 had a 50% reduction in PERK (P < 0.001). In NGP cells, over-expression of GRP78 increased levels of all three UPR activators with marked ≈3-fold increases in IRE1 and ATF6 (P < 0.0001) and a small increase in PERK (P<0.05). ***, P <0.001; **, P < 0.01; *, P<0.05; the direction (increase or decrease) of significant change is indicated by an arrow.
Figure 8:
Change in drug-induced stress intensity as a result of GRP78 over-expression. A, the induction of ROS 6 h after treatment of wild-type (c; open bars), vector-transfected (v; grey bars) or GRP78-over-expressing (G; black bars) cells with fenretinide (10 M or 5 M for melanoma/glioblastoma and neuroblastoma cells, respectively). Over-expression of GRP78 inhibited fenretinide-induced ROS in WM266-4 and MO59J cells (one-way ANOVA, P < 0.0001) but not in NGP neuroblastoma cells (one-way ANOVA, P > 0.05). B, the induction of ubiquitinated proteins 8 and 24 h after treatment of wild-type (c; open bars), vectortransfected (v; grey bars) or GRP78-over-expressing (G; black bars) cells with bortezomib (200 nM or 20 nM for melanoma/glioblastoma and neuroblastoma cells, respectively; bar heights are relative to wild-type cells). Accumulation of ubiquitin-tagged proteins was reduced by over-expression of GRP78 in WM266-4 and MO59J cells (one-way ANOVA, P<0.05) but increased in NGP neuroblastoma cells (P < 0.001). Error bars are 95% CI. ***, P <0.001; **, P < 0.01; *, P<0.05; the direction (increase or decrease) of significant change is indicated by an arrow.
